Idelalisib Intermediate CAS 870281-85-9 98% In Stock
Idelalisib intermediate CAS:870281-85-9 is intermediate to make Idelalisib, which is a second-line drug for patients whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab, idelalisib is to be used in patients for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions.
Idelalisib intermediate CAS:870281-85-9 is building block in the synthesis of Idelalisib, which is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell and small lymphocytic lymphoma.
Idelalisib intermediate CAS:870281-85-9 has a molecular formula of C22H24FN3O3, a molecular weight of 397.44.
Idelalisib intermediate CAS 870281-85-9 98% in stock